Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., plans to use part of the excess raised funds to permanently supplement its working capital, which has been approved by its board and supervisory board, and will be submitted for shareholder approval [1][6]. Fundraising Overview - The company issued 21,508,335 shares at a price of 56.56 RMB per share, raising a total of 1,216,511,427.60 RMB, with a net amount of 1,110,744,306.58 RMB after deducting issuance costs of 105,767,121.02 RMB [1][2]. - The funds were deposited in a special account approved by the board, and a tripartite supervision agreement was signed with the sponsor and the bank [2]. Investment Project Details - The net amount raised is 111,074.43 million RMB, with 99,718.47 million RMB allocated to the project for producing 190 tons of high-end pharmaceutical products, leaving an excess of 31,074.43 million RMB [3]. Previous Use of Excess Funds - The company has previously used 18,000 million RMB of excess funds for permanent working capital, with the latest approval for an additional 9,000 million RMB to be used for the same purpose [4][6]. Current Plan for Excess Funds - The company intends to use 9,000 million RMB of excess funds for permanent working capital, which constitutes 28.96% of the total excess funds, and will not exceed 30% [5]. - This plan will be implemented after the previous use of excess funds has been completed for 12 months, ensuring compliance with regulatory requirements [5]. Commitments and Explanations - The company commits that the cumulative use of excess funds for working capital will not exceed 30% of the total excess funds and will not affect the funding needs of investment projects [5][6]. Review Procedures and Opinions - The board and supervisory board have approved the use of excess funds for working capital, stating that it will enhance the efficiency of fund usage without affecting investment projects [6][7].